These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 26154322)
1. Activation of spleen tyrosine kinase (Syk) at fertilization in Rhinella arenarum eggs. Mouguelar VS; Coux G Int J Dev Biol; 2014; 58(10-12):811-8. PubMed ID: 26154322 [TBL] [Abstract][Full Text] [Related]
2. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391 [TBL] [Abstract][Full Text] [Related]
4. The integrin-binding motif RGDS induces protein tyrosine phosphorylation without activation in Bufo arenarum (Amphibia) oocytes. Mouguelar VS; Cabada MO; Coux G Reproduction; 2011 May; 141(5):581-93. PubMed ID: 21339287 [TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine kinases Syk and ZAP-70 display distinct requirements for Src family kinases in immune response receptor signal transduction. Zoller KE; MacNeil IA; Brugge JS J Immunol; 1997 Feb; 158(4):1650-9. PubMed ID: 9029101 [TBL] [Abstract][Full Text] [Related]
6. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849 [TBL] [Abstract][Full Text] [Related]
8. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia. Feng G; Wang X Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708 [TBL] [Abstract][Full Text] [Related]
9. Discovery and development of spleen tyrosine kinase (SYK) inhibitors. Singh R; Masuda ES; Payan DG J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213 [No Abstract] [Full Text] [Related]
10. Syk kinase is phosphorylated in specific areas of the developing nervous system. Hatterer E; Benon A; Chounlamountri N; Watrin C; Angibaud J; Jouanneau E; Boudin H; Honnorat J; Pellier-Monnin V; Noraz N Neurosci Res; 2011 Jun; 70(2):172-82. PubMed ID: 21354221 [TBL] [Abstract][Full Text] [Related]
11. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events. Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434 [TBL] [Abstract][Full Text] [Related]
12. Suboptimal B-cell antigen receptor signaling activity in vivo elicits germinal center counterselection mechanisms. Königsberger S; Weis V; Prodöhl J; Stehling M; Hobeika E; Reth M; Kiefer F Eur J Immunol; 2015 Feb; 45(2):603-11. PubMed ID: 25382621 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845 [TBL] [Abstract][Full Text] [Related]
14. Can treating the SYK cell cure leukemia? Downing JR Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569 [TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway. Lin YC; Huang DY; Chu CL; Lin WW Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367 [TBL] [Abstract][Full Text] [Related]
16. Structural and biophysical characterization of the Syk activation switch. Grädler U; Schwarz D; Dresing V; Musil D; Bomke J; Frech M; Greiner H; Jäkel S; Rysiok T; Müller-Pompalla D; Wegener A J Mol Biol; 2013 Jan; 425(2):309-33. PubMed ID: 23154170 [TBL] [Abstract][Full Text] [Related]
17. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk. Zhao H; Caflisch A Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110 [TBL] [Abstract][Full Text] [Related]
18. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694 [TBL] [Abstract][Full Text] [Related]
19. Spleen tyrosine kinase mediates high glucose-induced transforming growth factor-β1 up-regulation in proximal tubular epithelial cells. Yang WS; Chang JW; Han NJ; Lee SK; Park SK Exp Cell Res; 2012 Sep; 318(15):1867-76. PubMed ID: 22659134 [TBL] [Abstract][Full Text] [Related]